BIOTECANADA
15 meetings with public office holders, May 23, 2025 to Apr 13, 2026.
375 meetings on record since the registry opened in 2008.
Meetings over time
- May 2025: 2 meetings, with Josh Swift, David Lee
- Jun 2025: 0 meetings
- Jul 2025: 1 meeting, with Ritu Banarjee, Rodrigo Arancibia
- Aug 2025: 1 meeting, with Sandenga Yeba
- Sep 2025: 3 meetings, with Mitch Davies, Lakshmi Krishnan, Paul Hébert, Philip Jennings, Ritu Banarjee
- Oct 2025: 0 meetings
- Nov 2025: 0 meetings
- Dec 2025: 0 meetings
- Jan 2026: 3 meetings, with Ritu Banarjee, Rodrigo Arancibia, David Lee
- Feb 2026: 3 meetings, with Manuela Tomic, Sandenga Yeba, Dominic LeBlanc, Marjorie Michel, Karim Bardeesy
- Mar 2026: 1 meeting, with Philip Jennings, Ritu Banerjee
- Apr 2026: 1 meeting, with Shalene Curtis-Micallef
May 2025peak 3 in a monthApr 2026
Hover or focus a month to see who was met.
What they lobby about
- Health14
- Industry13
- Agriculture12
- Economic Development11
- International Trade9
- Research and Development8
- Intellectual Property7
- Environment6
- Budget5
- Science and Technology5
- Internal Trade3
- International Relations2
- Taxation and Finance1
The registry's own subject categories, chosen by the lobbyist on each filing. Each one opens its own page.
Who they met
Liberal3 met · 3 meetings
Not in Arena's member list16 met · 27 meetings
- Ritu Banarjee
- Sandenga Yeba
- David Lee
- Manuela Tomic
- Philip Jennings
- Rodrigo Arancibia
- Shalene Curtis-Micallef
- Janice Charette
- Josh Swift
- Justine Frame
- Lakshmi Krishnan
- Martin Moen
- Mitch Davies
- Nasser Haidar
- Paul Hébert
- Ritu Banerjee
Innovation, Science and Economic Development Canada (ISED) (12) · Health Canada (HC) (8) · House of Commons (4) · National Research Council (NRC) (2) · Prime Minister's Office (PMO) (1) · Global Affairs Canada (GAC) (1)
In their own words
- INTELLECTUAL PROPERTY/PATENT POLICY AND REGULATIONS in respect of creating Canada as one of the world's most competitive jurisdictions in protecting IP (e.g., match level of European Union via CETA negotiations)
- Policy measures to ensure security of drug supply in Canada and preserve Canada's attractiveness for biopharmaceutical launches, including in response to foreign pricing regulations.
- SUBMISSION REVIEW PROCESS FOR BIOLOGICS, COST RECOVERY REVIEW to ensure Canada remains competitive overall and any new costs do not put bioloigics are a comparative disadvantage
Meetings from the Commissioner of Lobbying of Canada. Canada does not require lobbyists to disclose what they spend, so there is no lobbying budget to report here — only the meetings they filed.